Informed Prostate Cancer Patient Support

Timing of High-Dose Rate Brachytherapy with External Beam Radiotherapy in intermediate and high-risk localised Prostate Cancer (THEPCA): a randomised trial - ScienceDirect sciencedirect.com Abstract Background HDR brachytherapy(HDR-BT) and external beam radiotherapy(EBRT) are effective treatments for prostate cancer(PC) but cause genitourinary(GU) and gastrointestinal(GI) toxicities. There is no consensus on the timing of HDR-BT in relation to EBRT and the effect of sequencing on patients. Objective The primary objective was to assess differences, if any, in the incidence of Grade 3 or higher GU toxicities from treatment. We also aimed to explore the incidence of G1-4 GI toxicities, quality of life and patient satisfaction. Suppression of PSA and signals for survival differences were also analysed. Methodology A single-centre randomised trial in intermediate and high-risk localised PC patients to receive HD

Quantifying Intrafraction Motion and the Impact of Gating for MRI-guided Stereotactic Radiotherapy for Prostate Cancer: Analysis of the MRI arm from the MIRAGE Phase III Randomized Trial - ScienceDirect :  sciencedirect.com Section snippets INTRODUCTION In recent years, there has been an increase in the use of hypofractionated radiotherapy 1 and ultrahypofractionated radiotherapy such as stereotactic body radiation therapy (SBRT) 2 in the treatment of prostate cancer. The use of SBRT as definitive treatment for prostate cancer doubled from 2010 to 2015 2 and has recently been endorsed by the National Comprehensive Cancer Network as a standard treatment option for localized prostate cancer of all risk groups. 3 The larger dose delivered per Radiation Planning and Delivery The MIRAGE trial was a phase III trial that randomized patients undergoing prostate SBR

Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision | Prostate Cancer and Prostatic Diseases nature.com Qin, Weijun Article Clinical Published: 30 December 2023 Jingliang Zhang 1   na1 , Yingmei Wang 3   na1 , Jianhua Jiao 1 , Zeyu Li 1 , Chaochao Cui 1 , Jian Chen 1 , Wenhui Yang 1 , Shuaijun Ma 1 , Peng Wu 1 , Yuming Jing 1 , Weihong Wen 4 , Fei Kang 5   na2 , Jing Wang 5   na2 & Weijun Qin   ORCID: orcid.org/0000-0002-7509-7164 1   na2   Prostate Cancer and Prostatic Diseases ( 2023 ) Cite this article

Urethra-sparing prostate cancer stereotactic body radiotherapy: sexual function and radiation dose to the penile bulb, the crura, and the internal pudendal arteries from a randomized phase 2 trial - International Journal of Radiation Oncology, Biology, Physics

Prostate‐specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma - Mackay - The Prostate - Wiley Online Library onlinelibrary.wiley.com Stephen Mackay PhD Abstract Introduction Prostate-specific membrane antigen (PSMA) is a US Food and Drug Administration-approved theranostic target for prostate cancer (PCa). Although PSMA is known to be glycosylated, the composition and functional roles of its N-linked glycoforms have not been fully characterized. Methods PSMA was isolated from pooled seminal plasma from low-risk grade Groups 1 and 2 PCa patients. Intact glycopeptides were analyzed by mass spectrometry to identify site-specific glycoforms.